ArticleMolecular therapy. Advances2026
Global age-related seroprevalence for adeno-associated virus serotype 9 immunoglobulin G.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adeno-associated virus serotype 9 antibody (AAV9-Ab) immunoglobulin G titers, which may vary according to region or age, are required to be tested to ensure individuals with spinal muscular atrophy (SMA) are within the ≤1:50 threshold and eligible for intravenous onasemnogene abeparvovec treatment. This cross-sectional analysis evaluated AAV9-Ab immunoglobulin G titers by region or country, year, and age in a population of individuals with SMA from a wide range of countries (excluding the United States and Japan). Anonymized serum samples were utilized for total AAV9-Ab immunoglobulin G enzyme-linked immunosorbent assay tests (2020-2025). A total of 4,149 samples from individuals with documented age and first test information from 75 countries were analyzed. AAV9-Ab immunoglobulin G data were similar by region, country, and year, except for a greater proportion of individuals with AAV9-Ab immunoglobulin G titers ≥1:100 from Russia compared with other countries. Individuals in the 0-month age group had greater likelihood of AAV9-Ab immunoglobulin G titers ≥1:100 than those in other age groups. Logistic regression analysis revealed that the predicted AAV9-Ab immunoglobulin G titer significance probability was elevated at 0 months, declined up to 12 months, and then steadily increased from 12 to 24 months of age. In conclusion, our analyses confirmed age-related AAV9-Ab immunoglobulin G seroprevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.